An Open-label, Single-arm clinical study to evaluate the Efficacy and Safety of Rumalaya Cream in common Musculoskeletal conditions

Himalaya Wellness Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年2月21日

试验速览

暂无简介。

•1.Subjects of either gender aged >=18 - <=65 years.
•2.Subjects presenting with pain due to common musculoskeletal conditions inclusive of any of the below:
•a Joints pain,
•b Neck pain inclusive of Cervical spondylosis
•c Shoulder pain inclusive of Frozen Shoulder
•d Low back pain inclusive of Lumbar spondylosis
•e Muscular pain
•f Muscular sprain.
•3.Subjects who are willing to refrain any topical applications during the study period.
•4.Subjects who are not on NSAIDs in the past 24 hours prior to screening.
•5.Subjects willing to sign informed consent and follow with the schedule of the study.
•6.Subjects who have not participated in similar kind of study in last 4 weeks.

•1.Subjects suffering from auto-immune disorders, spastic disorders, genetic disorders and severe traumatic conditions.
•2.Any evidence or history of hypersensitivity to any of the components in the Rumalaya cream.
•3.Any known skin disorder or presence of open wounds.
•4.Subjects who are on opioid analgesics and steroid medication will be excluded.
•5.Clinical diagnosis of bruises, trauma, muscle damage.
•6.Subjects with raw wounds, sutures, fractures and hematoma.
•7.Pregnant or lactating women/women not willing to follow adequate standard contraceptive measures.

发起方